- Home
- CHY vs INBX Comparison
CHY vs INBX Comparison
Compare CHY & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHY | INBX |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 999.7M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | CHY | INBX |
|---|---|---|
| Price | $13.02 | $106.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $150.00 |
| AVG Volume (30 Days) | 232.9K | ★ 453.4K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 10.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $10.32 | $12.80 |
| 52 Week High | $13.11 | $155.29 |
Technical Indicators
Market Signals| Indicator | CHY | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 61.61 | 47.69 |
| Support Level | $11.28 | $69.30 |
| Resistance Level | $13.11 | $153.14 |
| Average True Range (ATR) | 0.26 | 13.14 |
| MACD | -0.00 | -3.41 |
| Stochastic Oscillator | 92.17 | 13.49 |
Price Performance
Historical ComparisonAbout CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.